

Supplement Tables:

1.1: The prevalence of comorbidities differed by number of comorbidities and types of cancer.

Type of cancer	>=1 comorbidity (%)	P-value	>=2 comorbidities (%)	P-value	>=3 comorbidities (%)	P-value	>=4 comorbidities (%)	P-value
Renal	0.58	0.96	0.55	0.73	0.53	0.70	0.92	0.08
Colon	2.18	0.33	2.35	0.04	2.57	0.008	2.99	0.002*
Prostate	4.25	0.49	3.77	0.06	3.54	0.02	3.28	0.06
Breast	5.50	0.54	5.65	0.75	6.22	0.09	7.23	0.001*
Lung	0.96	0.01	1.06	0.008	1.49	<0.0001	1.62	0.0001*

*p<0.05

The prevalence for other types of cancers such as brain, ovary, uterus and stomach were very less therefore they were not included.

1.2: Prevalence by number of comorbidities among cancer survivors and non-cancer participants

Number of Comorbidities	Cancer Survivors (%)	Non-Cancer Survivors (%)	P-value
>=1 comorbidity	89.2	88.4	0.54
>=2 comorbidities	67.4	68.2	0.65
>=3 comorbidities	42.3	40.3	0.18
>=4 comorbidities	20.6	17.6	0.006*

*p<0.05

1.3: Healthcare utilization among cancer survivors by cancer type

Rate of	Renal		Colon		Prostate		Breast		Lung	
	(%)	P-value	(%)	P-value	(%)	P-value	(%)	P-value	(%)	P-value
Hospitalization	34.06	0.001	22.67	0.005	16.82	0.77	14.13	0.16	32.61	<0.001
Rehospitalization	29.16	0.32	44.45	0.39	42.20	0.58	36.26	0.50	52.00	0.01
Hospital readmissions within 30 days	14.0	0.96	11.29	0.28	10.76	0.11	10.46	0.09	14.84	0.70
Emergency Department (ED) Visits	7.70	0.36	10.93	0.70	9.12	0.38	11.25	0.49	12.81	0.60
≥2 ED visits	18.04	0.66	33.08	0.22	25.88	0.61	26.19	0.40	22.04	0.86
ED visit within 30 days of prior ED visit	8.72	0.89	10.33	0.89	9.66	0.98	15.1	0.05	9.91	0.97